Ishita Drugs

{
  "main_header": {
    "sid": 444125,
    "name": "Ishita Drugs",
    "stock_name": "Ishita Drugs",
    "full_name": "Ishita Drugs & Industries Ltd",
    "name_url": "stocks-analysis/ishita-drugs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "77.78",
    "chg": 0.67,
    "chgp": "0.87%",
    "dir": 1,
    "prev_price": "77.11",
    "mcapval": "22.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524400,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE806D01016",
    "curr_date": "Aug 04, 03:30 PM",
    "curr_time": "03:29 AM",
    "last_traded_at": "Aug 04, 03:30 PM IST",
    "bse_nse_vol": "2.13 k",
    "exc_status": "Active",
    "traded_date": "Aug 04, 2026",
    "traded_date_str": "2026 08 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ishita-drugs-444125-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Ishita Drugs & Industries Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-ltd-upgraded-to-sell-on-technical-improvements-despite-weak-fundamentals-4135748",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/IshitaDrugsIndu_mojoScore_4135748.png",
        "date": "2026-08-04 08:25:32",
        "description": "Ishita Drugs & Industries Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators despite ongoing challenges in financial performance and valuation metrics. The company’s technical outlook has improved to mildly bullish, prompting the revision, although fundamental weaknesses persist in profitability and debt servicing capacity."
      },
      {
        "title": "Ishita Drugs Declines 7.90% Amid Strong Sell Downgrade and Valuation Shifts",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-declines-790-amid-strong-sell-downgrade-and-valuation-shifts-4051504",
        "imagepath": "",
        "date": "2026-06-13 13:12:44",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>8 June:</strong> Downgrade to Strong Sell rating amid valuation and financial concerns</p>\n                    <p><strong>10 June:</strong> Valuation metrics shift from fair to attractive, signalling renewed price appeal</p>\n                    <p><strong>12 June:</strong> Stock closes the week at ₹75.06, down 7.90% for the week</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">₹81.50</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">₹75.06</div><div class=\"stat-change negative\">-7.90%</div>..."
      },
      {
        "title": "Ishita Drugs & Industries Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-ltd-valuation-shifts-signal-renewed-price-attractiveness-4043147",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/IshitaDrugsIndu_valuationdot_4043147.png",
        "date": "2026-06-10 08:00:42",
        "description": "Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite ongoing market headwinds and a recent downgrade in its overall mojo grade to Strong Sell. This recalibration in price-to-earnings and price-to-book value metrics invites a closer examination of the stock’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Ishita Drugs & Industries Ltd Downgraded to Strong Sell Amid Valuation and Financial Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-ltd-downgraded-to-strong-sell-amid-valuation-and-financial-concerns-4040432",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/IshitaDrugsIndu_mojoScore_4040432.png",
        "date": "2026-06-09 08:28:14",
        "description": "Ishita Drugs & Industries Ltd has been downgraded from a Sell to a Strong Sell rating as of 8 June 2026, reflecting deteriorating fundamentals and valuation pressures. The pharmaceutical company’s Mojo Score has dropped to 23.0, signalling heightened risk for investors amid weak financial trends, stretched valuation metrics, and unfavourable technical indicators."
      },
      {
        "title": "Ishita Drugs & Industries Ltd: Valuation Shift Signals Price Attractiveness Change",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-ltd-valuation-shift-signals-price-attractiveness-change-4032684",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/IshitaDrugsIndu_valuationdot_4032684.png",
        "date": "2026-06-03 08:00:26",
        "description": "Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, reflecting a change in price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector. This article analyses the implications of these valuation changes, comparing key metrics such as price-to-earnings (P/E) and price-to-book value (P/BV) ratios against industry benchmarks and historical trends, providing investors with a comprehensive view of the stock’s current standing."
      },
      {
        "title": "Are Ishita Drugs & Industries Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-ishita-drugs-industries-ltd-latest-results-good-or-bad-4024797",
        "imagepath": "",
        "date": "2026-05-31 19:20:43",
        "description": "Ishita Drugs & Industries Ltd's latest financial results for Q4 FY26 reveal significant operational challenges. The company reported net sales of ₹3.06 crores, reflecting a sequential decline of 2.55% from the previous quarter and a substantial year-on-year decrease of 32.89%. This pattern of revenue contraction indicates a troubling trend, particularly given the erratic sales performance over recent quarters, which has seen fluctuations ranging from a high of ₹5.40 crores to the current low.\n\nOn the profit side, the net profit for the quarter was ₹0.18 crores, which represents a 12.50% increase compared to the previous quarter, although it is down 37.93% year-on-year. This improvement in net profit is largely attributed to a significant increase in other income, which raises questions about the sustainability of earnings derived from core operations.\n\nOperating margins have also come under pressure, declin..."
      },
      {
        "title": "Ishita Drugs Q4 FY26: Revenue Decline and Margin Pressure Test Micro-Cap Pharma Player",
        "link": "https://www.marketsmojo.com/news/result-analysis/ishita-drugs-q4-fy26-revenue-decline-and-margin-pressure-test-micro-cap-pharma-player-4024534",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/IshitaDrugsIndu_quaterlyResult_4024534.png",
        "date": "2026-05-30 23:48:50",
        "description": "Ishita Drugs & Industries Ltd., an Ahmedabad-based active pharmaceutical ingredient (API) manufacturer, reported challenging Q4 FY26 results marked by significant revenue contraction and margin compression. The company posted a net profit of ₹0.18 crores for the quarter ended March 2026, representing a 12.50% increase quarter-on-quarter but a concerning 37.93% decline year-on-year. With a modest market capitalisation of ₹24.00 crores, the micro-cap pharma player faces mounting operational headwinds as it navigates a difficult industry environment."
      },
      {
        "title": "Ishita Drugs & Industries Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-ltd-valuation-shifts-signal-renewed-price-attractiveness-4004181",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/IshitaDrugsIndu_valuationdot_4004181.png",
        "date": "2026-05-22 08:00:21",
        "description": "Ishita Drugs & Industries Ltd has witnessed a notable improvement in its valuation parameters, shifting from a fair to an attractive rating. This change comes amid a complex market backdrop where the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios have adjusted favourably relative to historical averages and peer benchmarks, signalling a potential opportunity for investors in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Ishita Drugs & Industries Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-ltd-is-rated-sell-4002791",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/IshitaDrugsIndu_mojoScore_4002791.png",
        "date": "2026-05-21 10:10:22",
        "description": "Ishita Drugs & Industries Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 May 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook."
      }
    ],
    "total": 124,
    "sid": "444125",
    "stock_news_url": "https://www.marketsmojo.com/news/ishita-drugs-industries-444125"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (LODR) Regulations 2015 For The Quarter Ended 30Th June 2026.",
      "datetime": "31-Jul-2026",
      "details": "Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2026 inter alia to consider and approve 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 30th June 2026. 2. Any other matter with permission of the Chair.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "09-Jul-2026",
      "details": "Compliance Certificate under regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 30th June 2026 as attached.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "27-Jun-2026",
      "details": "The trading window for dealing in securities of the Company by designated persons stands closed from Wednesday 1st July 2026 till 48 hours after the declaration of the Unaudited Financial Results for the quarter ended 30th June 2026 .",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "08 Aug 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Ishita Drugs & Industries Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals

2026-08-04 08:25:32

Ishita Drugs & Industries Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators despite ongoing challenges in financial performance and valuation metrics. The company’s technical outlook has improved to mildly bullish, prompting the revision, although fundamental weaknesses persist in profitability and debt servicing capacity.

Read full news article

Ishita Drugs Declines 7.90% Amid Strong Sell Downgrade and Valuation Shifts

2026-06-13 13:12:44

Key Events This Week

8 June: Downgrade to Strong Sell rating amid valuation and financial concerns

10 June: Valuation metrics shift from fair to attractive, signalling renewed price appeal

12 June: Stock closes the week at ₹75.06, down 7.90% for the week

Week Open

₹81.50

Week Close

₹75.06

-7.90%

...

Read full news article

Ishita Drugs & Industries Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-06-10 08:00:42

Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite ongoing market headwinds and a recent downgrade in its overall mojo grade to Strong Sell. This recalibration in price-to-earnings and price-to-book value metrics invites a closer examination of the stock’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.

Read full news article

Ishita Drugs & Industries Ltd Downgraded to Strong Sell Amid Valuation and Financial Concerns

2026-06-09 08:28:14

Ishita Drugs & Industries Ltd has been downgraded from a Sell to a Strong Sell rating as of 8 June 2026, reflecting deteriorating fundamentals and valuation pressures. The pharmaceutical company’s Mojo Score has dropped to 23.0, signalling heightened risk for investors amid weak financial trends, stretched valuation metrics, and unfavourable technical indicators.

Read full news article

Ishita Drugs & Industries Ltd: Valuation Shift Signals Price Attractiveness Change

2026-06-03 08:00:26

Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, reflecting a change in price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector. This article analyses the implications of these valuation changes, comparing key metrics such as price-to-earnings (P/E) and price-to-book value (P/BV) ratios against industry benchmarks and historical trends, providing investors with a comprehensive view of the stock’s current standing.

Read full news article

Are Ishita Drugs & Industries Ltd latest results good or bad?

2026-05-31 19:20:43

Ishita Drugs & Industries Ltd's latest financial results for Q4 FY26 reveal significant operational challenges. The company reported net sales of ₹3.06 crores, reflecting a sequential decline of 2.55% from the previous quarter and a substantial year-on-year decrease of 32.89%. This pattern of revenue contraction indicates a troubling trend, particularly given the erratic sales performance over recent quarters, which has seen fluctuations ranging from a high of ₹5.40 crores to the current low. On the profit side, the net profit for the quarter was ₹0.18 crores, which represents a 12.50% increase compared to the previous quarter, although it is down 37.93% year-on-year. This improvement in net profit is largely attributed to a significant increase in other income, which raises questions about the sustainability of earnings derived from core operations. Operating margins have also come under pressure, declin...

Read full news article

Ishita Drugs Q4 FY26: Revenue Decline and Margin Pressure Test Micro-Cap Pharma Player

2026-05-30 23:48:50

Ishita Drugs & Industries Ltd., an Ahmedabad-based active pharmaceutical ingredient (API) manufacturer, reported challenging Q4 FY26 results marked by significant revenue contraction and margin compression. The company posted a net profit of ₹0.18 crores for the quarter ended March 2026, representing a 12.50% increase quarter-on-quarter but a concerning 37.93% decline year-on-year. With a modest market capitalisation of ₹24.00 crores, the micro-cap pharma player faces mounting operational headwinds as it navigates a difficult industry environment.

Read full news article

Ishita Drugs & Industries Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-05-22 08:00:21

Ishita Drugs & Industries Ltd has witnessed a notable improvement in its valuation parameters, shifting from a fair to an attractive rating. This change comes amid a complex market backdrop where the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios have adjusted favourably relative to historical averages and peer benchmarks, signalling a potential opportunity for investors in the Pharmaceuticals & Biotechnology sector.

Read full news article

Ishita Drugs & Industries Ltd is Rated Sell

2026-05-21 10:10:22

Ishita Drugs & Industries Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 May 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

View All News